About crizotinib
ALK and ROS1 tyrosine kinase inhibitor
Used for
- Treats certain ALK-positive or ROS1-positive non-small cell lung cancers.
- Treats certain ALK-positive anaplastic large cell lymphomas in children and young adults.
Usual adult dose
250 mg by mouth twice daily; dose may be reduced for side effects or organ problems.
Usual dose in children
For ALK-positive lymphoma, dosing is based on body surface area, twice daily; specialist supervision required.
Common side effects
- Vision changes
- Nausea, diarrhea, vomiting, or constipation
- Swelling, fatigue, or reduced appetite
- Abnormal liver tests
Important warnings
- Can cause serious liver injury; liver tests are monitored.
- May cause lung inflammation, heart rhythm problems, or a slow heartbeat.
- Can harm an unborn baby; effective contraception is needed during treatment and afterward.
- Do not open or crush capsules; swallow whole.
Pregnancy
May cause fetal harm. Avoid during pregnancy; use effective contraception during treatment and for 45 days after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for 45 days after the last dose.
Interactions
- Strong CYP3A inhibitors, such as clarithromycin, can raise crizotinib levels.
- Strong CYP3A inducers, such as rifampin, can lower crizotinib levels.
- Crizotinib can raise levels of some medicines, including certain statins and heart-rhythm drugs.
- Avoid medicines that prolong the QT interval when possible.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.